Parkinson's Disease Treatment Market Share, Size, Statistics, Demand and Forecast 2022-2027
IMARC Group, a leading market research company, has recently releases report titled “Parkinson's Disease Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027.” The study provides a detailed analysis of the industry, including the global parkinson's disease treatment market share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
How big is the parkinson's disease treatment market?
The global parkinson's disease treatment market is expected to exhibit a CAGR of 6.23% during 2022-2027.
What is parkinson's disease treatment?
Parkinson's disease represents a progressive neurological disorder characterized by the degeneration of motor neurons in the brain. Symptoms of the condition include rigidity, tremors, difficulty walking, motor impairment, depression, and dementia. Treatment options for Parkinson's disease encompass medications, supportive therapies, and surgical procedures, such as deep brain stimulation. In addition to this, drugs commonly used in the treatment of this condition include carbidopa-levodopa medicines, dopamine agonists, monoamine oxidase B (MAO B) inhibitors, catechol O-methyltransferase (COMT) inhibitors, and anticholinergics. These treatment approaches effectively manage the symptoms of Parkinson's disease, offering comfort to patients experiencing seizures.
Note: We are in the process of updating our reports. If you want to receive the latest research data covering the time period from 2023 to 2028, along with industry trends, market size, and competitive analysis, click on the request sample report. The team would be able to deliver the latest version of the report in a quick turnaround time.
Get the Sample Report: https://www.imarcgroup.com/parkinsons-disease-treatment-market/requestsample
What are the growth prospects and trends in the parkinson's disease treatment industry?
The escalating prevalence of this disorder and the increasing geriatric population, which is particularly vulnerable to neurodegenerative conditions, are among the primary factors driving the Parkinson's disease treatment market. Besides this, the rising awareness in individuals toward the available treatment alternatives for this condition is further augmenting the market growth. Moreover, the growing popularity of COMT inhibitors among healthcare providers and patients, as they are administered alongside co-therapeutic agents and carbidopa-levodopa therapy to maximize efficacy, is also catalyzing the global market.
![]() |
| Parkinson's Disease Treatment Market Report 2023-2028 |
Apart from this, continuous innovations in disease treatment methods, such as the development of neurostimulation tools, gene therapy, and neural transplantation procedures, are acting as significant growth-inducing factors. In line with this, the elevating requirement for advanced techniques to prolong the effects of constant dopaminergic stimulation medications and slow down the disease progression is also stimulating the market growth.
Furthermore, the ongoing improvements in healthcare infrastructure and the extensive research and development (R&D) activities by the leading pharmaceutical organizations are expected to bolster the Parkinson's disease treatment market in the coming years.
Parkinson's Disease Treatment Companies Covered:
- AbbVie Inc.
- Acadia Pharmaceuticals Inc.
- Boehringer Ingelheim International GmbH (C. H. Boehringer Sohn AG & Co. KG)
- Hoffmann-La Roche AG
- GlaxoSmithKline Plc
- Lundbeck A/S
- Merck & Co. Inc.
- Mylan N.V.
- Novartis AG
- Orion Corporation
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries
- Wockhardt Ltd.
Key Market Segmentation:
The report has segmented the market into the following categories:
Breakup by Drug Class:
- Carbidopa/Levodopa
- Dopamine Receptor Agonists
- MAO Inhibitors
- COMT Inhibitors
- Anticholinergics
- Others
Breakup by Route of Administration:
- Oral
- Transdermal
- Subcutaneous
- Intestinal Infusion
- Others
Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Breakup by Region:
- North America
- Asia-Pacific
- Europe
- Latin America
- Middle East and Africa
Speak to Analyst: https://www.imarcgroup.com/request?type=report&id=2792&flag=C
Key Highlights of the Report:
- Market Performance (2016-2021)
- Market Outlook (2022-2027)
- Market Trends
- Market Drivers and Success Factors
- Impact of COVID-19
- Value Chain Analysis
- Comprehensive mapping of the competitive landscape
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
USA: +1-631-791-1145 | Asia: +91-120-433-0800
Email: sales@imarcgroup.com
Follow us on Twitter: @imarcglobal
LinkedIn: https://www.linkedin.com/company/imarc-group/mycompany/
